Navigation Links
MicroRNA that could be used to suppress prostate cancer progression found
Date:5/16/2014

CINCINNATIAbout one in seven men will develop prostate cancer over the course of a lifetime, and about one in 36 men will die from it.

This is why findings by Cincinnati Cancer Center researchers, showing that a tumor suppressive microRNA, when activated by an anti-estrogen drug, could contribute to development of future targeted therapies, are important.

These findings are published in the May 16, 2014 edition of the journal PLOS ONE.

"MicroRNAs, or miRNAs, are short RNA molecules that play a prominent role in regulating gene expression. One miRNA can target multiple genes, but their expression is often hijacked by cancer cells and disrupts multiple cancer-causing or tumor-suppressing pathways," says Shuk-Mei Ho, PhD, director of the CCC and Jacob G. Schmidlapp Chair of Environmental Health and professor at the University of Cincinnati (UC) College of Medicine.

She along with Ricky Y.K. Leung, PhD, member of the CCC, assistant research professor in the department of environmental health and member of the UC Cancer Institute, and their team identified a new miRNA, known as hsa-miR-765, which is specifically activated by a Food and Drug Administration (FDA)-approved anti-estrogen drug (fulvestrant).

"This miRNA suppresses expression of HMGA1, a gene that was shown in previous studies to be associated with prostate cancer progression and recurrence," says Leung. "These findings do not only contribute to new insights on the effects of anti-estrogen but also the potential of using miRNA for monitoring drug efficacy and for future RNA-based therapy developments.

"This study also highlights the potential use of this anti-estrogen or miRNA in patients with recurrent prostate cancer, for whom there is no treatment, and raises the possibility of using anti-estrogen or miRNA treatments in preventing or slowing progression for primary prostate cancer."

Using cultured prostate cancer specimens from patients who were given a single 250 mg dose of fulvestrant, researchers found that hsa-miR-765 acted as a tumor suppressor when its expression was increased by the use of fulvestrant.

"Both the anti-estrogen and the hsa-miR-765 mimic suppressed HMGA1 protein expression," Ho says. "Levels of hsa-miR-765 were increased, and HMGA1 expression was almost completely lost in prostate cancer specimens from patients treated with a single dose of fulvestrant 28 days before removal of their prostate glands.

"These findings reveal a unique fulvestrant signaling process involving the increased regulation of hsa-miR-765 that suppresses the HMGA1 protein as part of the mechanism underlying the tumor suppressor action in prostate cancer. This could lead to newer treatment options with less toxicity for these patients."


'/>"/>
Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. MicroRNA could be key target for bowel cancer treatment
2. Fruit fly microRNA research at Rutgers-Camden offers clues to aging process
3. Viral microRNAs responsible for causing AIDS-related cancer, new USC study shows
4. Wayne State to study role of microRNAs in prostate cancer racial disparities
5. MicroRNA-31 might predict lung-cancer spread
6. Versatile microRNAs choke off cancer blood supply, suppress metastasis
7. Loss of MicroRNA decoy might contribute to development of soft-tissue sarcoma
8. New papers identify a microRNA that drives both cancer onset and metastasis
9. Moffitt Cancer Center researchers say 1 specific microrna promotes tumor growth and cancer spread
10. Atherosclerosis: Specific microRNAs promote inflammation
11. MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology: